Brauchle E, Noor S, Holtorf E, Garbe C, Schenke-Layland K, Busch C
Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Stuttgart, Germany; University Women's Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany; University of Stuttgart, Institute for Interfacial Engineering and Plasma Technology (IGVP), Stuttgart, Germany.
Clin Exp Dermatol. 2014 Jul;39(5):636-45. doi: 10.1111/ced.12357.
Raman spectroscopy is an optical noninvasive screening technology that generates individual fingerprints of living cells by reflecting their molecular constitution.
To discriminate melanoma cells from melanocytes, to identify drug-induced melanoma cell death stages (apoptosis, necrosis, autophagy) and to assess the susceptibility of melanoma cells to anticancer therapy.
We used Raman spectroscopy on normal and melanoma cells, and on wild-type (WT) and mutant melanoma cells, to investigate whether the technique could distinguish between different types of cells, identify mutations and evaluate response to anticancer therapy.
Using the multivariate principal component analysis of the Raman spectra, melanocytes could be distinguished from melanoma cells, and WT melanoma cells could be distinguished from melanoma cells with BRAF or NRAS mutations. When we used the apoptosis inducer staurosporine, the necrosis inducer 3-bromopyruvate and the autophagy inducer resveratrol to induce cell death in SKMEL28 melanoma cells, Raman spectroscopy clearly distinguished between these three types of cell death, as confirmed by immunoblotting. Finally, the technique could discriminate between different melanoma cell lines according to their susceptibility to high-dose ascorbate.
Raman spectroscopy is a powerful noninvasive tool to distinguish between melanocytes and melanoma cells, to analyze the specific type of cell death in melanoma cells, and to predict the susceptibility of melanoma cells to anticancer drugs.
拉曼光谱是一种光学非侵入性筛查技术，通过反映活细胞的分子组成来生成其个体指纹图谱。
区分黑色素瘤细胞和黑素细胞，识别药物诱导的黑色素瘤细胞死亡阶段（凋亡、坏死、自噬），并评估黑色素瘤细胞对抗癌治疗的敏感性。
我们对正常细胞和黑色素瘤细胞、野生型（WT）和突变型黑色素瘤细胞使用拉曼光谱，以研究该技术是否能够区分不同类型的细胞、识别突变并评估对抗癌治疗的反应。
通过对拉曼光谱进行多变量主成分分析，黑素细胞可与黑色素瘤细胞区分开来，WT黑色素瘤细胞可与具有BRAF或NRAS突变的黑色素瘤细胞区分开来。当我们使用凋亡诱导剂星形孢菌素、坏死诱导剂3-溴丙酮酸和自噬诱导剂白藜芦醇诱导SKMEL28黑色素瘤细胞死亡时，拉曼光谱清楚地区分了这三种类型的细胞死亡，免疫印迹法证实了这一点。最后，该技术可以根据不同黑色素瘤细胞系对高剂量抗坏血酸的敏感性进行区分。
拉曼光谱是一种强大的非侵入性工具，可用于区分黑素细胞和黑色素瘤细胞，分析黑色素瘤细胞中细胞死亡的具体类型，并预测黑色素瘤细胞对抗癌药物的敏感性。
